Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Pentosan Polysulfate: Oral Versus Subcutaneous Injection in Mucopolysaccharidosis Type I Dogs.

Simonaro CM, Tomatsu S, Sikora T, Kubaski F, Frohbergh M, Guevara JM, Wang RY, Vera M, Kang JL, Smith LJ, Schuchman EH, Haskins ME.

PLoS One. 2016 Apr 11;11(4):e0153136. doi: 10.1371/journal.pone.0153136.

2.

Variant CJD. 18 years of research and surveillance.

Diack AB, Head MW, McCutcheon S, Boyle A, Knight R, Ironside JW, Manson JC, Will RG.

Prion. 2014;8(4):286-95. doi: 10.4161/pri.29237. Review.

3.

Prion protein-specific antibodies that detect multiple TSE agents with high sensitivity.

McCutcheon S, Langeveld JP, Tan BC, Gill AC, de Wolf C, Martin S, Gonzalez L, Alibhai J, Blanco AR, Campbell L, Hunter N, Houston EF.

PLoS One. 2014 Mar 7;9(3):e91143. doi: 10.1371/journal.pone.0091143.

4.

Postmortem findings in a case of variant Creutzfeldt-Jakob disease treated with intraventricular pentosan polysulfate.

Newman PK, Todd NV, Scoones D, Mead S, Knight RS, Will RG, Ironside JW.

J Neurol Neurosurg Psychiatry. 2014 Aug;85(8):921-4. doi: 10.1136/jnnp-2013-305590.

6.

Rapidly progressive dementias and the treatment of human prion diseases.

Appleby BS, Lyketsos CG.

Expert Opin Pharmacother. 2011 Jan;12(1):1-12. doi: 10.1517/14656566.2010.514903. Review.

7.

Sulfated dextrans enhance in vitro amplification of bovine spongiform encephalopathy PrP(Sc) and enable ultrasensitive detection of bovine PrP(Sc).

Murayama Y, Yoshioka M, Masujin K, Okada H, Iwamaru Y, Imamura M, Matsuura Y, Fukuda S, Onoe S, Yokoyama T, Mohri S.

PLoS One. 2010 Oct 4;5(10). pii: e13152. doi: 10.1371/journal.pone.0013152.

8.

Toxic effects of intracerebral PrP antibody administration during the course of BSE infection in mice.

Lefebvre-Roque M, Kremmer E, Gilch S, Zou WQ, Féraudet C, Gilles CM, Salès N, Grassi J, Gambetti P, Baron T, Schätzl H, Lasmézas CI.

Prion. 2007 Jul-Sep;1(3):198-206.

9.

The efficacy of tetracyclines in peripheral and intracerebral prion infection.

De Luigi A, Colombo L, Diomede L, Capobianco R, Mangieri M, Miccolo C, Limido L, Forloni G, Tagliavini F, Salmona M.

PLoS One. 2008 Mar 26;3(3):e1888. doi: 10.1371/journal.pone.0001888.

10.

Long term survival in a patient with variant Creutzfeldt-Jakob disease treated with intraventricular pentosan polysulphate.

Parry A, Baker I, Stacey R, Wimalaratna S.

J Neurol Neurosurg Psychiatry. 2007 Jul;78(7):733-4.

11.

Enhanced antiscrapie effect using combination drug treatment.

Kocisko DA, Caughey B, Morrey JD, Race RE.

Antimicrob Agents Chemother. 2006 Oct;50(10):3447-9.

12.

Potent antiscrapie activities of degenerate phosphorothioate oligonucleotides.

Kocisko DA, Vaillant A, Lee KS, Arnold KM, Bertholet N, Race RE, Olsen EA, Juteau JM, Caughey B.

Antimicrob Agents Chemother. 2006 Mar;50(3):1034-44.

13.

A porphyrin increases survival time of mice after intracerebral prion infection.

Kocisko DA, Caughey WS, Race RE, Roper G, Caughey B, Morrey JD.

Antimicrob Agents Chemother. 2006 Feb;50(2):759-61.

14.

Inhibition of protease-resistant prion protein formation in a transformed deer cell line infected with chronic wasting disease.

Raymond GJ, Olsen EA, Lee KS, Raymond LD, Bryant PK 3rd, Baron GS, Caughey WS, Kocisko DA, McHolland LE, Favara C, Langeveld JP, van Zijderveld FG, Mayer RT, Miller MW, Williams ES, Caughey B.

J Virol. 2006 Jan;80(2):596-604.

Supplemental Content

Support Center